Factors associated with Glycemia Risk Index in a cohort of patients with type 1 Diabetes Mellitus and Latent Autoimmune Diabetes In Adults (LADA).
Continuous glucose monitoring
Glycemia risk index
Latent autoimmune diabetes in adults
Time in range
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
06 Jun 2024
06 Jun 2024
Historique:
received:
02
02
2024
accepted:
28
05
2024
medline:
7
6
2024
pubmed:
7
6
2024
entrez:
6
6
2024
Statut:
aheadofprint
Résumé
To analyze the degree of control based on classical glucometric parameters and Glycemia Risk Index (GRI) in real-life conditions in a cohort of patients with type 1 Diabetes Mellitus (DM) and Latent Autoimmune Diabetes in Adults (LADA) and to assess the factors that are associated with GRI. Cross-sectional study. 447 adult patients with type 1 DM and LADA users of Intermittent Continuous Glucose Monitoring (iCGM) with an adherence ≥ 70% were included. GRI was calculated with its Hypoglycemia (CHypo) and Hyperglycemia (CHyper) Components. Multivariate linear regression analysis was performed to evaluate the factors associated with GRI. Mean age 44.6 years (SD 13.7); 57.7% men; 83.9% type 1 DM; 16.1% LADA; time of evolution 20.6 years (SD 12.3). In patients with type 1 DM vs. LADA, differences were observed in relation to age [-11.1 years (SD 1.7)], age of onset [-21.9 years (DE 1.5)], time of evolution [11.7 years (DE 1.5)], treatment modality (p < 0.001), Time in Range (TIR) [-6.3% (SD 2.2)], Time Below Range (TBR) [1.9% (SD 0.6)], TBR level 1 (TBR1) [1.4% (SD 0.5)], Time Above Range (TAR) level 2 (TAR2) [4.7% (SD 1.3)], Coefficient of Variation (CV) [4.6% (SD 0.9)], GRI [11.3% (SD 2.8)], CHypo [1.3% (SD 0.5)] and CHyper [4.8% (SD 1.7)]. The variables that were independently associated with GRI were TIR (β = -1.34; CI 95% -1.43 to -1.25; p < 0.001), Glucose Management Indicator (GMI) (β = -5.82; CI 95% -7.59 to -4.05; p < 0.001), CV (β = 0.67; CI 95% 0.57 to 0.77; p < 0.001) and adherence to sensor usage (β = -0.16; CI 95% -1.27 to -0.06; p < 0.002). LADA present better control according to some glucometric parameters and a low GRI. However, the type of DM is not a factor that is independently associated with GRI.
Identifiants
pubmed: 38844609
doi: 10.1007/s12020-024-03901-5
pii: 10.1007/s12020-024-03901-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
International Diabetes Federation. IDF Diabetes Atlas. 10ª ed. Bruselas; 2021.
Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial, Diabetes control and complications trial research group. J. Pediatr. 125(2), 177–188 (1994)
N.H. White, P.A. Cleary, W. Dahms, D. Goldstein, J. Malone, W.V. Tamborlane, Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J. Pediatr. 139(6), 804–812 (2001).
doi: 10.1067/mpd.2001.118887
pubmed: 11743505
R.R. Holman, S.K. Paul, M.A. Bethel, D.R. Matthews, H.A. Neil, 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med 359(15), 1577–1589 (2008)
doi: 10.1056/NEJMoa0806470
pubmed: 18784090
E. Maddaloni, N. Lessan, A. Al Tikriti, R. Buzzetti, P. Pozzilli, M.T. Barakat, Latent autoimmune diabetes in adults in the United Arab Emirates: clinical features and factors related to insulin-requirement. PLoS ONE 10, e0131837 (2015)
doi: 10.1371/journal.pone.0131837
pubmed: 26252955
pmcid: 4529198
Z. Zhou, Y. Xiang, L. Ji, W. Jia, G. Ning, G. Huang, L. Yang, J. Lin, Z. Liu, W.A. Hagopian, R.D. Leslie; LADA China Study Group, Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study. Diabetes 62(2), 543–550 (2013)
doi: 10.2337/db12-0207
pubmed: 23086039
pmcid: 3554388
M.I. Hawa, H. Kolb, N. Schloot, H. Beyan, S.A. Paschou, R. Buzzetti, D. Mauricio, A. De Leiva, K. Yderstraede, H. Beck-Neilsen, J. Tuomilehto, C. Sarti, C. Thivolet, D. Hadden, S. Hunter, G. Schernthaner, W.A. Scherbaum, R. Williams, S. Brophy, P. Pozzilli, R.D. Leslie; Action LADA consortium, Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7. Diab. Care 36(4), 908–913 (2013)
doi: 10.2337/dc12-0931
V. Tyndall, R.H. Stimson, N.N. Zammitt, S.A. Ritchie, J.A. McKnight, A.R. Dover et al. Marked improvement in HbA1c following commencement of flash glucose monitoring in people with type 1 diabetes. Diabetologia 62(8), 1349–1356 (2019)
doi: 10.1007/s00125-019-4894-1
pubmed: 31177314
pmcid: 6647076
G. Yadegarfar, S.G. Anderson, Z. Khawaja, G. Cortes, K. Leivesley, A. Metters et al. The FreeStyle Libre flash glucose monitoring system: how it has improved glycaemic control for people with type 1 diabetes in Eastern Cheshire, UK. Cardiovasc Endocrinol. Metab. 9(4), 171–176 (2020)
doi: 10.1097/XCE.0000000000000216
pubmed: 33225233
pmcid: 7673768
M. Evans, Z. Welsh, A. Seibold, Reductions in HbA1c with Flash Glucose Monitoring are sustained for up to 24 months: a meta-analysis of 75 real-world observational studies. Diab. Ther. 13(6), 1175–1185 (2022)
doi: 10.1007/s13300-022-01253-9
K. Eeg-Olofsson, A.M. Svensson, S. Franzén, H. Ahmed Ismail, M. Törnblom, F. Levrat-Guillen, Real-world study of flash glucose monitoring among adults with type 2 diabetes within the Swedish National Diabetes Register. Diab Vasc. Dis. Res 20(1), 14791641211067418 (2023)
doi: 10.1177/14791641211067418
pubmed: 36715353
pmcid: 9903025
F. Gomez-Peralta, T. Dunn, K. Landuyt, Y. Xu, J.F. Merino-Torres, Flash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from Spain. BMJ Open Diab. Res Care 8(1), e001052 (2020)
doi: 10.1136/bmjdrc-2019-001052
pubmed: 32198165
pmcid: 7103828
R. Jiménez-Sahagún, E. Gómez Hoyos, G. Díaz Soto, M.O. Nieto de la Marca, M. Sánchez Ibáñez, S. Del Amo Simón et al. Impact of flash glucose monitoring on quality of life and glycaemic control parameters in adults with type 1 diabetes mellitus. Endocrinol. Diab. Nutr. 69(5), 345–353 (2022).
M.P. Bahíllo-Curieses, G. Díaz-Soto, A.M. Vidueira-Martínez, I. Torres-Ballester, E. Gómez-Hoyos, D. de Luis-Román, Assessment of metabolic control and use of flash glucose monitoring systems in a cohort of pediatric, adolescents, and adults patients with Type 1 diabetes. Endocrine 73(1), 47–51 (2021)
doi: 10.1007/s12020-021-02691-4
pubmed: 33754313
E. Fernández, A. Cortazar, V. Bellido, Impact of COVID-19 lockdown on glycemic control in patients with type 1 diabetes. Diab. Res Clin. Pr. 166, 108348 (2020)
doi: 10.1016/j.diabres.2020.108348
C. Eberle, S. Stichling, Impact of COVID-19 lockdown on glycemic control in patients with type 1 and type 2 diabetes mellitus: a systematic review. Diabetol. Metab. Syndr. 13(1), 95 (2021)
doi: 10.1186/s13098-021-00705-9
pubmed: 34493317
pmcid: 8423337
J. Moreno-Fernandez, J. Sastre, S. Herranz, P. Pinés, F.J. Gomez, I. Quiroga, A.J. Moya, C. Gonzalvo, R. Miralles, D. Calderon-Vicente, M. Palma, J. Gargallo, J.R. Muñoz-Rodriguez, Effect of the historic Spanish heatwave over glycemic control in adult patients with type 1 diabetes. Sci. Total Environ. 16, 164045 (2023)
doi: 10.1016/j.scitotenv.2023.164045
D.C. Klonoff, J. Wang, D. Rodbard, M.A. Kohn, C. Li, D. Liepmann et al. A Glycemia Risk Index (GRI) of hypoglycemia and hyperglycemia for continuous glucose monitoring validated by clinician ratings. J. Diab. Sci. Technol. 17(5), 1226–1242 (2023)
doi: 10.1177/19322968221085273
P. Pérez-López, P. Férnandez-Velasco, P. Bahillo-Curieses, D. de Luis, G. Díaz-Soto, Impact of glucose variability on the assessment of the glycemia risk index (GRI) and classic glycemic metrics. Endocrine 82(3), 560–568 (2023)
doi: 10.1007/s12020-023-03511-7
pubmed: 37695452
pmcid: 10618378
J.Y. Kim, J.H. Yoo, J.H. Kim, Comparison of glycemia risk index with time in range for assessing glycemic quality. Diab. Technol. Ther. 25(12), 883–892 (2023)
doi: 10.1089/dia.2023.0264
C. Piona, M. Marigliano, C. Roncarà, E. Mozzillo, F. Di Candia, A. Zanfardino et al. Glycemia risk index as a novel metric to evaluate the safety of glycemic control in children and adolescents with type 1 diabetes: an observational, multicenter, real-life cohort study. Diab. Technol. Ther. 25(7), 507–512 (2023)
doi: 10.1089/dia.2023.0040
T. Battelino, T. Danne, R.M. Bergenstal, S.A. Amiel, R. Beck et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diab. Care 42(8), 1593–1603 (2019)
doi: 10.2337/dci19-0028
R. Buzzetti, T. Tuomi, D. Mauricio, M. Pietropaolo, Z. Zhou, P. Pozzilli, R.D. Leslie, Management of latent autoimmune diabetes in adults: a consensus statement from an international expert panel. Diabetes 69(10), 2037–2047 (2020)
doi: 10.2337/dbi20-0017
pubmed: 32847960
pmcid: 7809717
P.Z. Zimmet, The pathogenesis and prevention of diabetes in adults: genes, autoimmunity, and demography. Diab. Care 18, 1050–1064 (1995)
doi: 10.2337/diacare.18.7.1050
N.A. ElSayed, G. Aleppo, V.R. Aroda, R.R. Bannuru, F.M. Brown, D. Bruemmer et al. On behalf of the American Diabetes Association. Classification and diagnosis of diabetes: standards of care in diabetes-2023. Diab. Care. 46, S19–S40 (2023)
doi: 10.2337/dc23-S002
A. Arranz Martín, E. Lecumberri Pascual, M.A. Brito Sanfiel, V. Andía Melero, L. Nattero Chavez, I. Sánchez López et al. Clinical and metabolic profile of patients with latent autoimmune diabetes in adults in specialized care in Madrid. Endocrinol. Diab. Nutr. 64(1), 34–39 (2017).
C.D. Andersen, L. Bennet, L. Nyström, U. Lindblad, E. Lindholm, L. Groop, O. Rolandsson, Worse glycaemic control in LADA patients than in those with type 2 diabetes, despite a longer time on insulin therapy. Diabetologia 56(2), 252–258 (2013)
doi: 10.1007/s00125-012-2759-y
pubmed: 23096095
R.S. Weinstock, D. Xing, D.M. Maahs, A. Michels, M.R. Rickels, A.L. Peters et al. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. J. Clin. Endocrinol. Metab. 98(8), 3411–3419 (2013)
doi: 10.1210/jc.2013-1589
pubmed: 23760624
C.M. Fuhri Snethlage, T.J. McDonald, R.D. Oram, P. De Groen, E. Rampanelli, A.W.M. Schimmel et al. Residual β-Cell function is associated with longer time in range in individuals with type 1 diabetes. Diabetes Care; dc230776. (2023). https://doi.org/10.2337/dc23-0776 . Epub ahead of print
T.D. Riddlesworth, R.W. Beck, R.L. Gal et al. Optimal sampling duration for continuous glucose monitoring to determine long-term glycemic control. Diab. Technol. Ther. 20(4), 314–316 (2018)
doi: 10.1089/dia.2017.0455
H.K. Akturk, P. Herrero, N. Oliver et al. Impact of different types of data loss on optimal continuous glucose monitoring sampling duration. Diab. Technol. Ther. 24(10), 749–753 (2022)
doi: 10.1089/dia.2022.0093
V.N. Shah, C. Sakamoto, L. Pyle, Optimal sampling duration for continuous glucose monitoring for the estimation of glycemia risk index. Diab. Technol. Ther. 25(2), 140–142 (2023)
doi: 10.1089/dia.2022.0401
E. Eviz, G. Yesiltepe Mutlu, K.E. Karakus, E. Can, T. Gokce, S. Muradoglu, S. Hatun, The advanced hybrid closed loop improves glycemia risk index, continuous glucose monitoring index, and time in range in children with type 1 diabetes: real-world data from a single center study. Diab. Technol. Ther. 25(10), 689–696 (2023)
doi: 10.1089/dia.2023.0112